Hemoglobinopathies, particularly sickle cell disease, pose major public health challenges in resource-limited settings, where delayed diagnosis contributes to high morbidity and mortality. As the world's most common monogenic disorder, the vast majority of affected individuals reside in sub-Saharan Africa. This study evaluated the performance of the HemoTypeSCTM rapid test for detecting hemoglobin A, S, and C variants, in accordance with the NF EN ISO 15189 standard. A prospective analytical study was conducted at the Biochemistry-Hematology Laboratory of Fann National University Hospital Center. Patients referred for hemoglobin electrophoresis were tested using HemoTypeSCTM, with the Emmel test and capillary electrophoresis (Capillarys 3 octa, Sebia) as comparative methods. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall agreement were calculated with 95% confidence intervals. Among the 126 samples, 19 had normal profiles and 107 had hemoglobinopathies. Compared with the Emmel test, HemoTypeSCTM showed 100% sensitivity and specificity. Compared with capillary electrophoresis, sensitivity was 98.16%, specificity 100%, PPV 100%, and NPV 90.48%. Two discrepancies in fine typing were observed among the 107 abnormal profiles, with no missed abnormal profiles. HemoTypeSCTM is a rapid, reliable, and easy-to-use test for first-line sickle cell disease screening in resource-limited settings. Positive results should be systematically confirmed by electrophoresis.
| Published in | Advances in Biochemistry (Volume 14, Issue 4) |
| DOI | 10.11648/j.ab.20261404.11 |
| Page(s) | 89-93 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2026. Published by Science Publishing Group |
Sickle Cell Disease, HemoTypeSCTM, Hemoglobinopathies, Method Verification
| [1] | Harteveld CL, Achour A, Arkesteijn SJG, Ter Huurne J, Verschuren M, Bhagwandien-Bisoen S, Schaap R, Vijfhuizen L, El Idrissi H, Koopmann TT. The hemoglobinopathies, molecular disease mechanisms and diagnostics. Int J Lab Hematol. 2022 Sep; 44 Suppl 1 (Suppl 1): 28-36. |
| [2] | Dahmani F, Benkirane S, Kouzih J, Woumki A, Mamad H, Masrar A. Profil épidémiologique des hémoglobinopathies: étude transversale descriptive autour du cas index [Epidemiological profile of hemoglobinopathies: a cross-sectional and descriptive index case study]. Pan Afr Med J. 2017 Jun 29; 27: 150. |
| [3] | Aimé AK, Etienne SM, Mbongi D, Nsonso D, Serrao E, Léon TMM, Oscar LN, Stanis WO. Dépistage hospitalier de la drépanocytose en République Démocratique du Congo (RDC) par HemoTypeSC: cas de la ville de Kindu [HemoTypeSC screening for sickle cell disease in the Democratic Republic of Congo (DRC): a case from the city of Kindu]. Pan Afr Med J. 2022 Feb 16; 41: 134. |
| [4] | EL MANHI S. Vérification de la méthode de dosage du potassium selon le COFRAC. Thèse, Université Mohammed V, Rabat; 2023. |
| [5] | Abdala AK, Shongo MYP, Tshilolo LMM, Shindano EM, Luboya ON, Wembonyama SO. Place de HemoTypeSC dans le dépistage de la drépanocytose àKindu, République Démocratique du Congo. Revue del’Infirmier Congolais. 2021; 5(1): 51-55. |
| [6] | Kakou Danho JB, Atiméré YN, Koné D, Yéo DD, Couitchéré L. Feasibility Study of the "HemoTypeSC" Test for the Rapid Screening of Sickle Cell Disease in Côte D'Ivoire. Adv Hematol. 2021 Mar 19; 2021: 8862039. |
| [7] | Adegoke SA, Oladimeji OI, Akinlosotu MA, Akinwumi AI, Matthew KA. HemoTypeSC point-of-care testing shows high sensitivity with alkaline cellulose acetate hemoglobin electrophoresis for screening hemoglobin SS and SC genotypes. Hematol Transfus Cell Ther. 2022 Jul-Sep; 44(3): 341-345. |
| [8] | Mukherjee MB, Colah RB, Mehta PR, Shinde N, Jain D, Desai S, Dave K, Italia Y, Raicha B, Serrao E. Multicenter Evaluation of HemoTypeSC as a Point-of-Care Sickle Cell Disease Rapid Diagnostic Test for Newborns and Adults Across India. Am J Clin Pathol. 2020 Jan 1; 153(1): 82-87. |
APA Style
Ndep, S. M., Matar, K. P., Kesso, B. N. O., Mareme, T. N., Siny, N., et al. (2026). Performance Evaluation of the HemoTypeSCTM Rapid Screening Test for the Detection of Hemoglobin A, S, and C Variants at the Fann National University Hospital. Advances in Biochemistry, 14(4), 89-93. https://doi.org/10.11648/j.ab.20261404.11
ACS Style
Ndep, S. M.; Matar, K. P.; Kesso, B. N. O.; Mareme, T. N.; Siny, N., et al. Performance Evaluation of the HemoTypeSCTM Rapid Screening Test for the Detection of Hemoglobin A, S, and C Variants at the Fann National University Hospital. Adv. Biochem. 2026, 14(4), 89-93. doi: 10.11648/j.ab.20261404.11
AMA Style
Ndep SM, Matar KP, Kesso BNO, Mareme TN, Siny N, et al. Performance Evaluation of the HemoTypeSCTM Rapid Screening Test for the Detection of Hemoglobin A, S, and C Variants at the Fann National University Hospital. Adv Biochem. 2026;14(4):89-93. doi: 10.11648/j.ab.20261404.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ab.20261404.11,
author = {Sene Moustapha Ndep and Kandji Pape Matar and Barry Nene Oumou Kesso and Thioune Ndeye Mareme and Ndiaye Siny and Djite Moustapha and Ndour El Malick and Gueye-Tall Fatou and Gueye Papa Madieye},
title = {Performance Evaluation of the HemoTypeSCTM Rapid Screening Test for the Detection of Hemoglobin A, S, and C Variants at the Fann National University Hospital},
journal = {Advances in Biochemistry},
volume = {14},
number = {4},
pages = {89-93},
doi = {10.11648/j.ab.20261404.11},
url = {https://doi.org/10.11648/j.ab.20261404.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ab.20261404.11},
abstract = {Hemoglobinopathies, particularly sickle cell disease, pose major public health challenges in resource-limited settings, where delayed diagnosis contributes to high morbidity and mortality. As the world's most common monogenic disorder, the vast majority of affected individuals reside in sub-Saharan Africa. This study evaluated the performance of the HemoTypeSCTM rapid test for detecting hemoglobin A, S, and C variants, in accordance with the NF EN ISO 15189 standard. A prospective analytical study was conducted at the Biochemistry-Hematology Laboratory of Fann National University Hospital Center. Patients referred for hemoglobin electrophoresis were tested using HemoTypeSCTM, with the Emmel test and capillary electrophoresis (Capillarys 3 octa, Sebia) as comparative methods. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall agreement were calculated with 95% confidence intervals. Among the 126 samples, 19 had normal profiles and 107 had hemoglobinopathies. Compared with the Emmel test, HemoTypeSCTM showed 100% sensitivity and specificity. Compared with capillary electrophoresis, sensitivity was 98.16%, specificity 100%, PPV 100%, and NPV 90.48%. Two discrepancies in fine typing were observed among the 107 abnormal profiles, with no missed abnormal profiles. HemoTypeSCTM is a rapid, reliable, and easy-to-use test for first-line sickle cell disease screening in resource-limited settings. Positive results should be systematically confirmed by electrophoresis.},
year = {2026}
}
TY - JOUR T1 - Performance Evaluation of the HemoTypeSCTM Rapid Screening Test for the Detection of Hemoglobin A, S, and C Variants at the Fann National University Hospital AU - Sene Moustapha Ndep AU - Kandji Pape Matar AU - Barry Nene Oumou Kesso AU - Thioune Ndeye Mareme AU - Ndiaye Siny AU - Djite Moustapha AU - Ndour El Malick AU - Gueye-Tall Fatou AU - Gueye Papa Madieye Y1 - 2026/10/23 PY - 2026 N1 - https://doi.org/10.11648/j.ab.20261404.11 DO - 10.11648/j.ab.20261404.11 T2 - Advances in Biochemistry JF - Advances in Biochemistry JO - Advances in Biochemistry SP - 89 EP - 93 PB - Science Publishing Group SN - 2329-0862 UR - https://doi.org/10.11648/j.ab.20261404.11 AB - Hemoglobinopathies, particularly sickle cell disease, pose major public health challenges in resource-limited settings, where delayed diagnosis contributes to high morbidity and mortality. As the world's most common monogenic disorder, the vast majority of affected individuals reside in sub-Saharan Africa. This study evaluated the performance of the HemoTypeSCTM rapid test for detecting hemoglobin A, S, and C variants, in accordance with the NF EN ISO 15189 standard. A prospective analytical study was conducted at the Biochemistry-Hematology Laboratory of Fann National University Hospital Center. Patients referred for hemoglobin electrophoresis were tested using HemoTypeSCTM, with the Emmel test and capillary electrophoresis (Capillarys 3 octa, Sebia) as comparative methods. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall agreement were calculated with 95% confidence intervals. Among the 126 samples, 19 had normal profiles and 107 had hemoglobinopathies. Compared with the Emmel test, HemoTypeSCTM showed 100% sensitivity and specificity. Compared with capillary electrophoresis, sensitivity was 98.16%, specificity 100%, PPV 100%, and NPV 90.48%. Two discrepancies in fine typing were observed among the 107 abnormal profiles, with no missed abnormal profiles. HemoTypeSCTM is a rapid, reliable, and easy-to-use test for first-line sickle cell disease screening in resource-limited settings. Positive results should be systematically confirmed by electrophoresis. VL - 14 IS - 4 ER -
Biochemistry-Hematology Laboratory, Fann University Hospital, Dakar, Senegal
Information